• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

squamous cell carcinoma

An arrow incrementally going up stairs before pointing straight up Blue background
Biotech

Merus touts cancer drug's strong profile with new data drop

Along with the company's new data drop, Merus also secured a partner for its first-in-class NRG1 fusion-positive cancer candidate.
Zoey Becker Dec 2, 2024 11:59am
end of the road road block shut down closed blocked

Replimune shares halve as skin cancer drug fails phase 2

Dec 5, 2023 10:35am
On target clinical trial success bullseye score

Checkpoint on track to add indications for cancer drug approval

Jun 16, 2022 3:49pm
Dragonfly bug insect

Gilead joins Big Pharma peers at Dragonfly's pond in $300M deal

May 2, 2022 9:50am
stop sign

Idera's only asset flounders as biotech, AbbVie end enrollment

Dec 15, 2021 11:15am
cash  money

Cedilla adds $25M to series B to test two cancer drugs in trials

Oct 25, 2021 6:30am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings